ATYR PHARMA INC

Profile

Company Names

ATYR PHARMA INC

Addresses

3545 JOHN HOPKINS COURT, STE #250, SAN DIEGO, CA 92121

3545 JOHN HOPKINS COURT, SUITE #250, SAN DIEGO, CA 92121

Phone Numbers

858-731-8389

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$122,128,737.00

Number of Funding Rounds:

2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2017-08-31 
$45,849,982.00 
$45,849,982.00 
$0.00 
Equity 
1
2015-03-31 
$76,278,755.00 
$76,278,755.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SRINI 
 
AKKARAJU 
DIRECTOR
SYNAGEVA BIOPHARMA CORP.   |  SMM SPV I, LLC   |  ATYR PHARMA INC   |  CHINOOK THERAPEUTICS U.S., INC.   |  A2 BIOTHERAPEUTICS, INC.
JAMES 
C. 
BLAIR 
DIRECTOR
ZOGENIX INC   |  DP VIII ASSOCIATES, L.P.   |  DOMAIN PARTNERS VIII, L.P.   |  INTEGENX INC   |  APPLIED PROTEOMICS, INC.   |  CLOVIS ONCOLOGY, INC.   |  DOMAIN PARTNERS IX, L.P.   |  ATYR PHARMA INC   |  GENE SCIENCES, INC.   |  AXIAL BIOTHERAPEUTICS, INC.   |  CHROMACODE, INC.   |  AXIAL THERAPEUTICS, INC.
JOHN 
T. 
BLAKE 
EXECUTIVE OFFICER
ATYR PHARMA INC   |  SECOND SIGHT MEDICAL PRODUCTS INC
FREDERIC 
 
CHEREAU 
EXECUTIVE OFFICER
PERVASIS THERAPEUTICS INC   |  ATYR PHARMA INC   |  LOGICBIO THERAPEUTICS, INC.
JOHN 
K. 
CLARKE 
DIRECTOR
VERASTEM, INC.   |  ATYR PHARMA INC   |  IVENIX, INC.   |  VIVIDION THERAPEUTICS, INC.   |  CARDINAL ANALYTX, INC.   |  CHP IV - WAREHOUSE LLC   |  PUNCHDOWN PARTNERS SPV-PR, LLC
TIMOTHY 
P. 
COUGHLIN 
DIRECTOR
FATE THERAPEUTICS INC   |  ATYR PHARMA INC
KATHRYN 
 
FALBERG 
DIRECTOR
ATYR PHARMA INC
MARK 
 
GOLDBERG 
DIRECTOR
SYNAGEVA BIOPHARMA CORP.   |  SYNAGEVA BIOPHARMA CORP   |  ATYR PHARMA INC   |  BUILT TECHNOLOGIES, INC.   |  PILOT.COM, INC.   |  BIOFEEDBACK DESIGN, INC.   |  KEEP TRUCKIN, INC.   |  MOTIVE TECHNOLOGIES, INC.   |  STIRLING HOTELS + RESORTS, INC.   |  CHEMISTRY VENTURES FUND I, L.P.   |  CHEMISTRY VENTURES FUND II-A, L.P.
JEFFREY 
S. 
HATFIELD 
DIRECTOR
ATYR PHARMA INC   |  MIRAGEN THERAPEUTICS, INC.
NANCY 
D. 
KRUEGER 
EXECUTIVE OFFICER
ATYR PHARMA INC
JOHN 
D. 
MENDLEIN 
EXECUTIVE OFFICER, DIRECTOR
ATYR PHARMA INC
AMIR 
 
NASHAT 
DIRECTOR
PROMEDIOR INC   |  AVILA THERAPEUTICS INC   |  PERVASIS THERAPEUTICS INC   |  FATE THERAPEUTICS INC   |  BIND BIOSCIENCES INC   |  SELECTA BIOSCIENCES INC   |  POLARIS VENTURE PARTNERS VI, L.P.   |  SUN CATALYTIX CORP   |  RECEPTOS, INC.   |  POLARIS ENTREPRENEURS- FUND VII, L.P.   |  POLARIS PARTNERS VII, L.P.   |  ATYR PHARMA INC   |  AGBIOME, LLC   |  METACRINE, INC.   |  SCHOLAR ROCK LLC   |  1366 TECHNOLOGIES INC   |  SOFREGEN MEDICAL INC.   |  POLARIS ENTREPRENEURS- FUND VIII, L.P.   |  SYROS PHARMACEUTICALS, INC.   |  SCHOLAR ROCK HOLDING CORP   |  CAMP4 THERAPEUTICS CORP   |  MORPHIC HOLDING, LLC   |  FREENOME HOLDINGS, INC.   |  PRIMMUNE THERAPEUTICS, INC.   |  MORPHIC HOLDING, INC.
AMIR 
H. 
NASHAT, SC.D. 
DIRECTOR
ATYR PHARMA INC   |  DEWPOINT THERAPEUTICS, INC.
ED 
 
PENHOET 
DIRECTOR
IMMUNE DESIGN CORP.   |  SCYNEXIS INC   |  ATYR PHARMA INC
SANUJ 
K. 
RAVINDRAN 
EXECUTIVE OFFICER
ATYR PHARMA INC
PAUL 
 
SCHIMMEL 
DIRECTOR
ABIDE THERAPEUTICS, INC.   |  KINDEX PHARMACEUTICALS, INC.   |  ATYR PHARMA INC   |  BORAGEN, INC.
SANJAY 
S. 
SHUKLA 
EXECUTIVE OFFICER
ATYR PHARMA INC
AKKARAJU 
 
SRINIVAS 
DIRECTOR
ATYR PHARMA INC
DAVID 
 
WEINER 
EXECUTIVE OFFICER
W-NET FUND I, L.P.   |  TCI FUND 1, LLC   |  TRILION CAPITAL CORP.   |  GOTHAM SEGREGATED ACCOUNT I, INC.   |  VERTIGO CAPITAL L P   |  ATYR PHARMA INC   |  AMANITA SPISSA REIT II, INC.   |  SREF REIT, INC. (MD)   |  GOTHAM II REIT, INC. (MD)   |  JOSHUA TREE CAPITAL, LP   |  TRILION CAPITAL FUND, LLC   |  BRIGHT MINDS BIOSCIENCES INC.   |  AXOSIM, INC.   |  28BIO, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2017-09-15
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2017-08-31 
2015-04-02
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2015-03-31 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
PIPER JAFFRAY + CO.
665